Cytokinetics, Incorporated (CYTK) 10-Year Financial Performance & Capital Metrics

CYTK • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersAlzheimer's & Neurodegenerative

AboutCytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Show more

Revenue $18M +145.3%
EBITDA -$527M -8.8%
Net Income -$590M -12.0%
EPS (Diluted) -5.26 +3.5%
Gross Margin -1737.22% +59.4%
EBITDA Margin -2851.13% +55.7%
Operating Margin -2902.72% +56.0%
Net Margin -3191.11% +54.3%
ROE -
ROIC -98.71% -10.5%
Debt/Equity -
Interest Coverage -6.20 +28.0%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 85 (top 15%)

✗Weaknesses

✗Negative free cash flow
✗Sales declining 7.2% over 5 years
✗Shares diluted 16.0% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-8.9%

5Y-7.22%

3Y-35.99%

TTM2609.26%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-30.45%

EPS CAGR

10Y-

5Y-

3Y-

TTM-17.1%

ROCE

10Y Avg-36.9%

5Y Avg-41.44%

3Y Avg-51.14%

Latest-55.18%

Peer Comparison

Alzheimer's & Neurodegenerative

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
ANVSAnnovis Bio, Inc.	84.81M	3.20	-0.00			-189.15%
CLNNClene Inc.	60.19M	5.11	-0.90	-47.71%	-142.5%	-17.38%
ABOSAcumen Pharmaceuticals, Inc.	112.67M	1.86	-1.09			-143.12%	0.16
BHVNBiohaven Ltd.	1.58B	11.92	-1.28			-198.83%	0.09
IKTInhibikase Therapeutics, Inc.	200.09M	1.65	-1.42	-100%		-65.37%	0.00
ALECAlector, Inc.	198.66M	1.82	-1.48	3.6%	-156.03%	-186.68%	0.34
CGTXCognition Therapeutics, Inc.	121.82M	1.38	-1.62			-76.61%	0.04
ATHEAlterity Therapeutics Limited	60M	3.31	-2.90	35.32%	-330.63%	-73.75%	0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	28.66M	106.41M	13.37M	31.5M	26.87M	55.83M	70.43M	94.59M	7.53M	18.47M
Revenue Growth %	-0.39%	2.71%	-0.87%	1.36%	-0.15%	1.08%	0.26%	0.34%	-0.92%	1.45%
Cost of Goods Sold+	46.4M	64.4M	90.3M	89.14M	86.13M	96.95M	159.94M	240.81M	330.12M	339.41M
COGS % of Revenue	1.62%	0.61%	6.75%	2.83%	3.21%	1.74%	2.27%	2.55%	43.84%	18.37%
Gross Profit+	-17.74M	42.01M	-76.93M	-57.63M	-59.26M	-41.12M	-89.51M	-146.22M	-322.59M	-320.93M
Gross Margin %	-0.62%	0.39%	-5.75%	-1.83%	-2.21%	-0.74%	-1.27%	-1.55%	-42.84%	-17.37%
Gross Profit Growth %	-8.06%	3.37%	-2.83%	0.25%	-0.03%	0.31%	-1.18%	-0.63%	-1.21%	0.01%
Operating Expenses+	19.67M	23.32M	36.47M	31.28M	39.61M	52.82M	96.8M	177.98M	173.61M	215.31M
OpEx % of Revenue	0.69%	0.22%	2.73%	0.99%	1.47%	0.95%	1.37%	1.88%	23.06%	11.65%
Selling, General & Admin	19.67M	27.82M	36.47M	31.28M	39.61M	52.82M	96.8M	177.98M	173.61M	215.31M
SG&A % of Revenue	0.69%	0.26%	2.73%	0.99%	1.47%	0.95%	1.37%	1.88%	23.06%	11.65%
Research & Development	46.4M	59.9M	90.3M	89.14M	86.13M	96.95M	159.94M	240.81M	330.12M	339.41M
R&D % of Revenue	1.62%	0.56%	6.75%	2.83%	3.21%	1.74%	2.27%	2.55%	43.84%	18.37%
Other Operating Expenses	-46.4M	-64.4M	-90.3M	-89.14M	-86.13M	-96.95M	-159.94M	-240.81M	-330.12M	-339.41M
Operating Income+	-37.41M	18.69M	-113.4M	-88.92M	-98.87M	-93.94M	-186.31M	-324.2M	-496.2M	-536.25M
Operating Margin %	-1.31%	0.18%	-8.48%	-2.82%	-3.68%	-1.68%	-2.65%	-3.43%	-65.9%	-29.03%
Operating Income Growth %	-1.54%	1.5%	-7.07%	0.22%	-0.11%	0.05%	-0.98%	-0.74%	-0.53%	-0.08%
EBITDA+	-36.82M	19.43M	-111.5M	-87.68M	-97.57M	-92.11M	-176.68M	-315.8M	-484.31M	-526.72M
EBITDA Margin %	-1.28%	0.18%	-8.34%	-2.78%	-3.63%	-1.65%	-2.51%	-3.34%	-64.32%	-28.51%
EBITDA Growth %	-1.58%	1.53%	-6.74%	0.21%	-0.11%	0.06%	-0.92%	-0.79%	-0.53%	-0.09%
D&A (Non-Cash Add-back)	589K	741K	1.9M	1.24M	1.29M	1.83M	9.64M	8.4M	11.89M	9.53M
EBIT	-37.25M	14.19M	-110.79M	-84.72M	-94.33M	-88.61M	-185.98M	-337.8M	-468.58M	-503.01M
Net Interest Income+	-94K	-2.23M	-14.39M	-17.37M	-22.82M	-33.35M	-29M	-39.81M	-30.04M	-34.98M
Interest Income	0	0	2.6M	4.19M	4.54M	5.33M	331K	11.34M	27.63M	51.53M
Interest Expense	94K	2.23M	17M	21.56M	27.36M	38.68M	29.33M	51.16M	57.67M	86.51M
Other Income/Expense	-94K	-2.23M	-14.39M	-17.37M	-22.82M	-33.35M	-29M	-64.75M	-30.04M	-53.28M
Pretax Income+	-37.5M	16.45M	-127.79M	-106.29M	-121.69M	-127.29M	-215.31M	-388.95M	-526.24M	-589.53M
Pretax Margin %	-1.31%	0.15%	-9.56%	-3.37%	-4.53%	-2.28%	-3.06%	-4.11%	-69.89%	-31.91%
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-37.5M	16.45M	-127.79M	-106.29M	-121.69M	-127.29M	-215.31M	-388.95M	-526.24M	-589.53M
Net Margin %	-1.31%	0.15%	-9.56%	-3.37%	-4.53%	-2.28%	-3.06%	-4.11%	-69.89%	-31.91%
Net Income Growth %	-1.56%	1.44%	-8.77%	0.17%	-0.14%	-0.05%	-0.69%	-0.81%	-0.35%	-0.12%
Net Income (Continuing)	-37.5M	16.45M	-127.79M	-106.29M	-121.69M	-127.29M	-215.31M	-388.95M	-526.24M	-589.53M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.97	0.39	-2.59	-1.95	-2.59	-1.97	-2.80	-4.33	-5.45	-5.26
EPS Growth %	-1.37%	1.4%	-7.64%	0.25%	-0.33%	0.24%	-0.42%	-0.55%	-0.26%	0.03%
EPS (Basic)	-0.97	0.41	-2.59	-1.95	-2.59	-1.97	-2.80	-4.33	-5.45	-5.26
Diluted Shares Outstanding	38.81M	42.56M	49.4M	54.42M	57.58M	64.52M	76.89M	89.83M	96.52M	111.98M
Basic Shares Outstanding	38.66M	39.94M	49.4M	54.42M	57.58M	64.52M	76.89M	89.83M	96.52M	111.98M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	113.11M	158.63M	274.3M	207.67M	233.75M	474.22M	535.67M	795.19M	628.05M	1.11B
Cash & Short-Term Investments	111.44M	156.25M	268.89M	198.73M	225.11M	464.06M	471.64M	782.58M	614.82M	1.08B
Cash Only	65.08M	66.87M	125.21M	42.26M	36.43M	82.98M	112.67M	65.58M	113.02M	94.86M
Short-Term Investments	46.37M	89.38M	143.69M	156.47M	188.68M	381.07M	358.97M	717M	501.8M	981.16M
Accounts Receivable	12K	24K	1.11M	6.79M	5.16M	4.42M	51.82M	147K	1.28M	16.65M
Days Sales Outstanding	0.15	0.08	30.36	78.62	70.14	28.9	268.56	0.57	62.19	328.96
Inventory	0	0	0	-6.79M	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	4.29M	0	0	0	0	12.46M	0	15.28M
Total Non-Current Assets+	2.13M	11.51M	20.52M	3.5M	56.06M	59.58M	305.65M	219.59M	196.26M	293.73M
Property, Plant & Equipment	1.75M	3.64M	3.57M	3.2M	13.41M	16.27M	146.41M	163.19M	147.74M	140.97M
Fixed Asset Turnover	16.37x	29.26x	3.75x	9.83x	2.00x	3.43x	0.48x	0.58x	0.05x	0.13x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	179K	7.67M	16.52M	0	42.65M	36.95M	152.05M	46.71M	40.53M	145.06M
Other Non-Current Assets	200K	200K	429K	300K	0	6.36M	7.19M	9.69M	8M	7.71M
Total Assets+	115.24M	170.14M	294.81M	211.18M	289.81M	533.8M	841.32M	1.01B	824.32M	1.4B
Asset Turnover	0.25x	0.63x	0.05x	0.15x	0.09x	0.10x	0.08x	0.09x	0.01x	0.01x
Asset Growth %	-0.13%	0.48%	0.73%	-0.28%	0.37%	0.84%	0.58%	0.21%	-0.19%	0.7%
Total Current Liabilities+	31.65M	33.26M	32.44M	22.19M	26.02M	31.2M	71.86M	84.62M	102.68M	179.67M
Accounts Payable	2.24M	4.24M	5.25M	3.76M	8.16M	8.05M	21.09M	25.61M	21.51M	20.37M
Days Payables Outstanding	17.61	24.01	21.23	15.41	34.58	30.31	48.12	38.82	23.78	21.9
Short-Term Debt	0	2.5M	0	2.61M	0	0	0	958K	10.08M	11.52M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	0	0	0	0	0	1000K
Other Current Liabilities	132K	415K	11.36M	66K	9.47M	12.84M	16.47M	22.89M	39.81M	21.11M
Current Ratio	3.57x	4.77x	8.45x	9.36x	8.98x	15.20x	7.45x	9.40x	6.12x	6.17x
Quick Ratio	3.57x	4.77x	8.45x	9.66x	8.98x	15.20x	7.45x	9.40x	6.12x	6.17x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	15M	42.52M	152.52M	163.05M	274.73M	389.22M	525.6M	1.04B	1.11B	1.36B
Long-Term Debt	14.64M	27.38M	31.78M	39.81M	129.26M	135.71M	142.84M	609.62M	607.37M	645.6M
Capital Lease Obligations	0	0	0	771K	2.19M	440K	112.23M	126.89M	120.43M	112.58M
Deferred Tax Liabilities	-359K	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	359K	142K	105.75M	122.47M	143.28M	166.07M	183.53M	301.55M	380.16M	599.19M
Total Liabilities	46.65M	75.78M	184.97M	185.24M	300.75M	420.42M	597.46M	1.12B	1.21B	1.54B
Total Debt+	14.64M	27.38M	31.78M	42.41M	136.07M	138.94M	269.93M	750.3M	755.77M	788.68M
Net Debt	-50.44M	-39.49M	-93.43M	157K	99.64M	55.95M	157.26M	684.72M	642.75M	693.82M
Debt / Equity	0.21x	0.29x	0.29x	1.64x	-	1.23x	1.11x	-	-	-
Debt / EBITDA	-	1.41x	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-2.03x	-	-	-	-	-	-	-	-
Interest Coverage	-397.95x	8.36x	-6.67x	-4.12x	-3.61x	-2.43x	-6.35x	-6.34x	-8.60x	-6.20x
Total Equity+	68.59M	94.36M	109.84M	25.93M	-10.94M	113.38M	243.86M	-107.9M	-386.32M	-135.37M
Equity Growth %	-0.25%	0.38%	0.16%	-0.76%	-1.42%	11.37%	1.15%	-1.44%	-2.58%	0.65%
Book Value per Share	1.77	2.22	2.22	0.48	-0.19	1.76	3.17	-1.20	-4.00	-1.21
Total Shareholders' Equity	68.59M	94.36M	109.84M	25.93M	-10.94M	113.38M	243.86M	-107.9M	-386.32M	-135.37M
Common Stock	40K	41K	54K	768.76M	59K	70K	84K	94K	102K	118K
Retained Earnings	-534.74M	-518.29M	-646.08M	-743.32M	-865.02M	-992.31M	-1.21B	-1.59B	-2.11B	-2.7B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	149K	137K	343K	500K	679K	149K	-869K	-3.59M	-10K	2.4M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	4.88M	36.98M	-101.76M	-101.22M	-90.91M	8.94M	-142.52M	-299.52M	-414.33M	-395.89M
Operating CF Margin %	0.17%	0.35%	-7.61%	-3.21%	-3.38%	0.16%	-2.02%	-3.17%	-55.02%	-21.43%
Operating CF Growth %	1.11%	6.57%	-3.75%	0.01%	0.1%	1.1%	-16.94%	-1.1%	-0.38%	0.04%
Net Income	-37.5M	16.45M	-127.79M	-106.29M	-121.69M	-127.29M	-215.31M	-388.95M	-526.24M	-589.53M
Depreciation & Amortization	589K	741K	1.92M	1.24M	1.29M	1.83M	2.28M	5.81M	11.89M	9.53M
Stock-Based Compensation	4.57M	7.15M	9.03M	9.76M	10.76M	17.62M	26.83M	47.85M	72.06M	97.84M
Deferred Taxes	-21K	-18K	-67K	0	0	-573K	2.84M	0	0	0
Other Non-Cash Items	3K	534K	14.66M	17.01M	22.62M	28.24M	32.38M	60.48M	24.86M	50.6M
Working Capital Changes	37.25M	12.13M	487K	-22.94M	-3.89M	89.12M	8.46M	-24.7M	3.09M	35.66M
Change in Receivables	46.63M	-12K	-1.09M	-1.12M	1.62M	743K	-47.4M	56.67M	-1.14M	-15.37M
Change in Inventory	2.6M	8.24M	-1.4M	4.91M	0	1.48M	0	0	0	0
Change in Payables	755K	1.7M	1.46M	-1.49M	4.4M	-110K	1.05M	4.52M	-3.48M	-4.48M
Cash from Investing+	16.06M	-52.08M	-65.83M	5.13M	-74.71M	-196.51M	-147.78M	-262.13M	239.25M	-553.1M
Capital Expenditures	-562K	-1.6M	-2.88M	-889K	-2.62M	-11.05M	-48.87M	-11.34M	-1.42M	-3.91M
CapEx % of Revenue	0.02%	0.01%	0.22%	0.03%	0.1%	0.2%	0.69%	0.12%	0.19%	0.21%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	1K	33K	-62.95M	14K	0	-185.46M	-98.91M	-250.8M	0	0
Cash from Financing+	23.91M	16.89M	225.92M	13.13M	159.79M	234.12M	319.98M	516.17M	221.32M	930.61M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	352K	1.9M	104.87M	3.23M	-11.99M	9.02M	7.93M	163.96M	57.94M	233.38M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	4.32M	35.39M	-104.64M	-102.1M	-93.53M	-2.11M	-191.39M	-310.85M	-415.75M	-399.8M
FCF Margin %	0.15%	0.33%	-7.83%	-3.24%	-3.48%	-0.04%	-2.72%	-3.29%	-55.21%	-21.64%
FCF Growth %	1.09%	7.19%	-3.96%	0.02%	0.08%	0.98%	-89.75%	-0.62%	-0.34%	0.04%
FCF per Share	0.11	0.83	-2.12	-1.88	-1.62	-0.03	-2.49	-3.46	-4.31	-3.57
FCF Conversion (FCF/Net Income)	-0.13x	2.25x	0.80x	0.95x	0.75x	-0.07x	0.66x	0.77x	0.79x	0.67x
Interest Paid	94K	1.9M	2.13M	2.88M	4.06M	0	0	0	10.29M	0
Taxes Paid	1K	1K	1K	1K	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-46.69%	20.19%	-125.16%	-156.57%	-1622.88%	-248.5%	-120.54%	-572.15%	-	-
Return on Invested Capital (ROIC)	-62.34%	38.39%	-238.62%	-313.79%	-129.19%	-54.61%	-48.99%	-49.73%	-89.33%	-98.71%
Gross Margin	-61.9%	39.48%	-575.46%	-182.96%	-220.55%	-73.66%	-127.09%	-154.59%	-4284.1%	-1737.22%
Net Margin	-130.86%	15.46%	-955.94%	-337.41%	-452.93%	-228%	-305.72%	-411.21%	-6988.63%	-3191.11%
Debt / Equity	0.21x	0.29x	0.29x	1.64x	-	1.23x	1.11x	-	-	-
Interest Coverage	-397.95x	8.36x	-6.67x	-4.12x	-3.61x	-2.43x	-6.35x	-6.34x	-8.60x	-6.20x
FCF Conversion	-0.13x	2.25x	0.80x	0.95x	0.75x	-0.07x	0.66x	0.77x	0.79x	0.67x
Revenue Growth	-38.95%	271.3%	-87.44%	135.64%	-14.71%	107.79%	26.15%	34.3%	-92.04%	145.34%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
Collaboration Revenues	-	-	-	-	-	-	3.47M
Collaboration Revenues Growth	-	-	-	-	-	-	-
Research And Development	-	-	-	10.57M	6.59M	4.03M	-
Research And Development Growth	-	-	-	-	-37.68%	-38.83%	-
Milestone	-	-	-	-	1M	3.5M	-
Milestone Growth	-	-	-	-	-	250.00%	-
License	5.13M	-	-	-	-	-	-
License Growth	-	-	-	-	-	-	-
Research And Development Milestone Grant And Other Revenues Net	-	13.8M	10M	7.4M	-	-	-
Research And Development Milestone Grant And Other Revenues Net Growth	-	-	-27.54%	-26.00%	-	-	-
Reimbursements	22.25M	13.11M	6.55M	-	-	-	-
Reimbursements Growth	-	-41.10%	-49.98%	-	-	-	-
Milestone Fees	2M	-	-	-	-	-	-
Milestone Fees Growth	-	-	-	-	-	-	-
Co Invest Option Payments	-	-	-	-	-	-	-
Co Invest Option Payments Growth	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Cytokinetics, Incorporated (CYTK) reported $87.2M in revenue for fiscal year 2024. This represents a 2080% increase from $4.0M in 2011.

Cytokinetics, Incorporated (CYTK) grew revenue by 145.3% over the past year. This is strong growth.

Cytokinetics, Incorporated (CYTK) reported a net loss of $751.9M for fiscal year 2024.

Dividend & Returns

Cytokinetics, Incorporated (CYTK) had negative free cash flow of $453.4M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Cytokinetics, Incorporated (CYTK) 10-Year Financial Performance & Capital Metrics

CYTK • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersAlzheimer's & Neurodegenerative

Revenue $18M +145.3%
EBITDA -$527M -8.8%
Net Income -$590M -12.0%
EPS (Diluted) -5.26 +3.5%
Gross Margin -1737.22% +59.4%
EBITDA Margin -2851.13% +55.7%
Operating Margin -2902.72% +56.0%
Net Margin -3191.11% +54.3%
ROE -
ROIC -98.71% -10.5%
Debt/Equity -
Interest Coverage -6.20 +28.0%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 85 (top 15%)

✗Weaknesses

✗Negative free cash flow
✗Sales declining 7.2% over 5 years
✗Shares diluted 16.0% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-8.9%

5Y-7.22%

3Y-35.99%

TTM2609.26%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-30.45%

EPS CAGR

10Y-

5Y-

3Y-

TTM-17.1%

ROCE

10Y Avg-36.9%

5Y Avg-41.44%

3Y Avg-51.14%

Latest-55.18%

Peer Comparison

Alzheimer's & Neurodegenerative

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
ANVSAnnovis Bio, Inc.	84.81M	3.20	-0.00			-189.15%
CLNNClene Inc.	60.19M	5.11	-0.90	-47.71%	-142.5%	-17.38%
ABOSAcumen Pharmaceuticals, Inc.	112.67M	1.86	-1.09			-143.12%	0.16
BHVNBiohaven Ltd.	1.58B	11.92	-1.28			-198.83%	0.09
IKTInhibikase Therapeutics, Inc.	200.09M	1.65	-1.42	-100%		-65.37%	0.00
ALECAlector, Inc.	198.66M	1.82	-1.48	3.6%	-156.03%	-186.68%	0.34
CGTXCognition Therapeutics, Inc.	121.82M	1.38	-1.62			-76.61%	0.04
ATHEAlterity Therapeutics Limited	60M	3.31	-2.90	35.32%	-330.63%	-73.75%	0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	28.66M	106.41M	13.37M	31.5M	26.87M	55.83M	70.43M	94.59M	7.53M	18.47M
Revenue Growth %	-0.39%	2.71%	-0.87%	1.36%	-0.15%	1.08%	0.26%	0.34%	-0.92%	1.45%
Cost of Goods Sold+	46.4M	64.4M	90.3M	89.14M	86.13M	96.95M	159.94M	240.81M	330.12M	339.41M
COGS % of Revenue	1.62%	0.61%	6.75%	2.83%	3.21%	1.74%	2.27%	2.55%	43.84%	18.37%
Gross Profit+	-17.74M	42.01M	-76.93M	-57.63M	-59.26M	-41.12M	-89.51M	-146.22M	-322.59M	-320.93M
Gross Margin %	-0.62%	0.39%	-5.75%	-1.83%	-2.21%	-0.74%	-1.27%	-1.55%	-42.84%	-17.37%
Gross Profit Growth %	-8.06%	3.37%	-2.83%	0.25%	-0.03%	0.31%	-1.18%	-0.63%	-1.21%	0.01%
Operating Expenses+	19.67M	23.32M	36.47M	31.28M	39.61M	52.82M	96.8M	177.98M	173.61M	215.31M
OpEx % of Revenue	0.69%	0.22%	2.73%	0.99%	1.47%	0.95%	1.37%	1.88%	23.06%	11.65%
Selling, General & Admin	19.67M	27.82M	36.47M	31.28M	39.61M	52.82M	96.8M	177.98M	173.61M	215.31M
SG&A % of Revenue	0.69%	0.26%	2.73%	0.99%	1.47%	0.95%	1.37%	1.88%	23.06%	11.65%
Research & Development	46.4M	59.9M	90.3M	89.14M	86.13M	96.95M	159.94M	240.81M	330.12M	339.41M
R&D % of Revenue	1.62%	0.56%	6.75%	2.83%	3.21%	1.74%	2.27%	2.55%	43.84%	18.37%
Other Operating Expenses	-46.4M	-64.4M	-90.3M	-89.14M	-86.13M	-96.95M	-159.94M	-240.81M	-330.12M	-339.41M
Operating Income+	-37.41M	18.69M	-113.4M	-88.92M	-98.87M	-93.94M	-186.31M	-324.2M	-496.2M	-536.25M
Operating Margin %	-1.31%	0.18%	-8.48%	-2.82%	-3.68%	-1.68%	-2.65%	-3.43%	-65.9%	-29.03%
Operating Income Growth %	-1.54%	1.5%	-7.07%	0.22%	-0.11%	0.05%	-0.98%	-0.74%	-0.53%	-0.08%
EBITDA+	-36.82M	19.43M	-111.5M	-87.68M	-97.57M	-92.11M	-176.68M	-315.8M	-484.31M	-526.72M
EBITDA Margin %	-1.28%	0.18%	-8.34%	-2.78%	-3.63%	-1.65%	-2.51%	-3.34%	-64.32%	-28.51%
EBITDA Growth %	-1.58%	1.53%	-6.74%	0.21%	-0.11%	0.06%	-0.92%	-0.79%	-0.53%	-0.09%
D&A (Non-Cash Add-back)	589K	741K	1.9M	1.24M	1.29M	1.83M	9.64M	8.4M	11.89M	9.53M
EBIT	-37.25M	14.19M	-110.79M	-84.72M	-94.33M	-88.61M	-185.98M	-337.8M	-468.58M	-503.01M
Net Interest Income+	-94K	-2.23M	-14.39M	-17.37M	-22.82M	-33.35M	-29M	-39.81M	-30.04M	-34.98M
Interest Income	0	0	2.6M	4.19M	4.54M	5.33M	331K	11.34M	27.63M	51.53M
Interest Expense	94K	2.23M	17M	21.56M	27.36M	38.68M	29.33M	51.16M	57.67M	86.51M
Other Income/Expense	-94K	-2.23M	-14.39M	-17.37M	-22.82M	-33.35M	-29M	-64.75M	-30.04M	-53.28M
Pretax Income+	-37.5M	16.45M	-127.79M	-106.29M	-121.69M	-127.29M	-215.31M	-388.95M	-526.24M	-589.53M
Pretax Margin %	-1.31%	0.15%	-9.56%	-3.37%	-4.53%	-2.28%	-3.06%	-4.11%	-69.89%	-31.91%
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-37.5M	16.45M	-127.79M	-106.29M	-121.69M	-127.29M	-215.31M	-388.95M	-526.24M	-589.53M
Net Margin %	-1.31%	0.15%	-9.56%	-3.37%	-4.53%	-2.28%	-3.06%	-4.11%	-69.89%	-31.91%
Net Income Growth %	-1.56%	1.44%	-8.77%	0.17%	-0.14%	-0.05%	-0.69%	-0.81%	-0.35%	-0.12%
Net Income (Continuing)	-37.5M	16.45M	-127.79M	-106.29M	-121.69M	-127.29M	-215.31M	-388.95M	-526.24M	-589.53M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.97	0.39	-2.59	-1.95	-2.59	-1.97	-2.80	-4.33	-5.45	-5.26
EPS Growth %	-1.37%	1.4%	-7.64%	0.25%	-0.33%	0.24%	-0.42%	-0.55%	-0.26%	0.03%
EPS (Basic)	-0.97	0.41	-2.59	-1.95	-2.59	-1.97	-2.80	-4.33	-5.45	-5.26
Diluted Shares Outstanding	38.81M	42.56M	49.4M	54.42M	57.58M	64.52M	76.89M	89.83M	96.52M	111.98M
Basic Shares Outstanding	38.66M	39.94M	49.4M	54.42M	57.58M	64.52M	76.89M	89.83M	96.52M	111.98M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	113.11M	158.63M	274.3M	207.67M	233.75M	474.22M	535.67M	795.19M	628.05M	1.11B
Cash & Short-Term Investments	111.44M	156.25M	268.89M	198.73M	225.11M	464.06M	471.64M	782.58M	614.82M	1.08B
Cash Only	65.08M	66.87M	125.21M	42.26M	36.43M	82.98M	112.67M	65.58M	113.02M	94.86M
Short-Term Investments	46.37M	89.38M	143.69M	156.47M	188.68M	381.07M	358.97M	717M	501.8M	981.16M
Accounts Receivable	12K	24K	1.11M	6.79M	5.16M	4.42M	51.82M	147K	1.28M	16.65M
Days Sales Outstanding	0.15	0.08	30.36	78.62	70.14	28.9	268.56	0.57	62.19	328.96
Inventory	0	0	0	-6.79M	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	4.29M	0	0	0	0	12.46M	0	15.28M
Total Non-Current Assets+	2.13M	11.51M	20.52M	3.5M	56.06M	59.58M	305.65M	219.59M	196.26M	293.73M
Property, Plant & Equipment	1.75M	3.64M	3.57M	3.2M	13.41M	16.27M	146.41M	163.19M	147.74M	140.97M
Fixed Asset Turnover	16.37x	29.26x	3.75x	9.83x	2.00x	3.43x	0.48x	0.58x	0.05x	0.13x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	179K	7.67M	16.52M	0	42.65M	36.95M	152.05M	46.71M	40.53M	145.06M
Other Non-Current Assets	200K	200K	429K	300K	0	6.36M	7.19M	9.69M	8M	7.71M
Total Assets+	115.24M	170.14M	294.81M	211.18M	289.81M	533.8M	841.32M	1.01B	824.32M	1.4B
Asset Turnover	0.25x	0.63x	0.05x	0.15x	0.09x	0.10x	0.08x	0.09x	0.01x	0.01x
Asset Growth %	-0.13%	0.48%	0.73%	-0.28%	0.37%	0.84%	0.58%	0.21%	-0.19%	0.7%
Total Current Liabilities+	31.65M	33.26M	32.44M	22.19M	26.02M	31.2M	71.86M	84.62M	102.68M	179.67M
Accounts Payable	2.24M	4.24M	5.25M	3.76M	8.16M	8.05M	21.09M	25.61M	21.51M	20.37M
Days Payables Outstanding	17.61	24.01	21.23	15.41	34.58	30.31	48.12	38.82	23.78	21.9
Short-Term Debt	0	2.5M	0	2.61M	0	0	0	958K	10.08M	11.52M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	0	0	0	0	0	1000K
Other Current Liabilities	132K	415K	11.36M	66K	9.47M	12.84M	16.47M	22.89M	39.81M	21.11M
Current Ratio	3.57x	4.77x	8.45x	9.36x	8.98x	15.20x	7.45x	9.40x	6.12x	6.17x
Quick Ratio	3.57x	4.77x	8.45x	9.66x	8.98x	15.20x	7.45x	9.40x	6.12x	6.17x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	15M	42.52M	152.52M	163.05M	274.73M	389.22M	525.6M	1.04B	1.11B	1.36B
Long-Term Debt	14.64M	27.38M	31.78M	39.81M	129.26M	135.71M	142.84M	609.62M	607.37M	645.6M
Capital Lease Obligations	0	0	0	771K	2.19M	440K	112.23M	126.89M	120.43M	112.58M
Deferred Tax Liabilities	-359K	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	359K	142K	105.75M	122.47M	143.28M	166.07M	183.53M	301.55M	380.16M	599.19M
Total Liabilities	46.65M	75.78M	184.97M	185.24M	300.75M	420.42M	597.46M	1.12B	1.21B	1.54B
Total Debt+	14.64M	27.38M	31.78M	42.41M	136.07M	138.94M	269.93M	750.3M	755.77M	788.68M
Net Debt	-50.44M	-39.49M	-93.43M	157K	99.64M	55.95M	157.26M	684.72M	642.75M	693.82M
Debt / Equity	0.21x	0.29x	0.29x	1.64x	-	1.23x	1.11x	-	-	-
Debt / EBITDA	-	1.41x	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-2.03x	-	-	-	-	-	-	-	-
Interest Coverage	-397.95x	8.36x	-6.67x	-4.12x	-3.61x	-2.43x	-6.35x	-6.34x	-8.60x	-6.20x
Total Equity+	68.59M	94.36M	109.84M	25.93M	-10.94M	113.38M	243.86M	-107.9M	-386.32M	-135.37M
Equity Growth %	-0.25%	0.38%	0.16%	-0.76%	-1.42%	11.37%	1.15%	-1.44%	-2.58%	0.65%
Book Value per Share	1.77	2.22	2.22	0.48	-0.19	1.76	3.17	-1.20	-4.00	-1.21
Total Shareholders' Equity	68.59M	94.36M	109.84M	25.93M	-10.94M	113.38M	243.86M	-107.9M	-386.32M	-135.37M
Common Stock	40K	41K	54K	768.76M	59K	70K	84K	94K	102K	118K
Retained Earnings	-534.74M	-518.29M	-646.08M	-743.32M	-865.02M	-992.31M	-1.21B	-1.59B	-2.11B	-2.7B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	149K	137K	343K	500K	679K	149K	-869K	-3.59M	-10K	2.4M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	4.88M	36.98M	-101.76M	-101.22M	-90.91M	8.94M	-142.52M	-299.52M	-414.33M	-395.89M
Operating CF Margin %	0.17%	0.35%	-7.61%	-3.21%	-3.38%	0.16%	-2.02%	-3.17%	-55.02%	-21.43%
Operating CF Growth %	1.11%	6.57%	-3.75%	0.01%	0.1%	1.1%	-16.94%	-1.1%	-0.38%	0.04%
Net Income	-37.5M	16.45M	-127.79M	-106.29M	-121.69M	-127.29M	-215.31M	-388.95M	-526.24M	-589.53M
Depreciation & Amortization	589K	741K	1.92M	1.24M	1.29M	1.83M	2.28M	5.81M	11.89M	9.53M
Stock-Based Compensation	4.57M	7.15M	9.03M	9.76M	10.76M	17.62M	26.83M	47.85M	72.06M	97.84M
Deferred Taxes	-21K	-18K	-67K	0	0	-573K	2.84M	0	0	0
Other Non-Cash Items	3K	534K	14.66M	17.01M	22.62M	28.24M	32.38M	60.48M	24.86M	50.6M
Working Capital Changes	37.25M	12.13M	487K	-22.94M	-3.89M	89.12M	8.46M	-24.7M	3.09M	35.66M
Change in Receivables	46.63M	-12K	-1.09M	-1.12M	1.62M	743K	-47.4M	56.67M	-1.14M	-15.37M
Change in Inventory	2.6M	8.24M	-1.4M	4.91M	0	1.48M	0	0	0	0
Change in Payables	755K	1.7M	1.46M	-1.49M	4.4M	-110K	1.05M	4.52M	-3.48M	-4.48M
Cash from Investing+	16.06M	-52.08M	-65.83M	5.13M	-74.71M	-196.51M	-147.78M	-262.13M	239.25M	-553.1M
Capital Expenditures	-562K	-1.6M	-2.88M	-889K	-2.62M	-11.05M	-48.87M	-11.34M	-1.42M	-3.91M
CapEx % of Revenue	0.02%	0.01%	0.22%	0.03%	0.1%	0.2%	0.69%	0.12%	0.19%	0.21%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	1K	33K	-62.95M	14K	0	-185.46M	-98.91M	-250.8M	0	0
Cash from Financing+	23.91M	16.89M	225.92M	13.13M	159.79M	234.12M	319.98M	516.17M	221.32M	930.61M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	352K	1.9M	104.87M	3.23M	-11.99M	9.02M	7.93M	163.96M	57.94M	233.38M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	4.32M	35.39M	-104.64M	-102.1M	-93.53M	-2.11M	-191.39M	-310.85M	-415.75M	-399.8M
FCF Margin %	0.15%	0.33%	-7.83%	-3.24%	-3.48%	-0.04%	-2.72%	-3.29%	-55.21%	-21.64%
FCF Growth %	1.09%	7.19%	-3.96%	0.02%	0.08%	0.98%	-89.75%	-0.62%	-0.34%	0.04%
FCF per Share	0.11	0.83	-2.12	-1.88	-1.62	-0.03	-2.49	-3.46	-4.31	-3.57
FCF Conversion (FCF/Net Income)	-0.13x	2.25x	0.80x	0.95x	0.75x	-0.07x	0.66x	0.77x	0.79x	0.67x
Interest Paid	94K	1.9M	2.13M	2.88M	4.06M	0	0	0	10.29M	0
Taxes Paid	1K	1K	1K	1K	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-46.69%	20.19%	-125.16%	-156.57%	-1622.88%	-248.5%	-120.54%	-572.15%	-	-
Return on Invested Capital (ROIC)	-62.34%	38.39%	-238.62%	-313.79%	-129.19%	-54.61%	-48.99%	-49.73%	-89.33%	-98.71%
Gross Margin	-61.9%	39.48%	-575.46%	-182.96%	-220.55%	-73.66%	-127.09%	-154.59%	-4284.1%	-1737.22%
Net Margin	-130.86%	15.46%	-955.94%	-337.41%	-452.93%	-228%	-305.72%	-411.21%	-6988.63%	-3191.11%
Debt / Equity	0.21x	0.29x	0.29x	1.64x	-	1.23x	1.11x	-	-	-
Interest Coverage	-397.95x	8.36x	-6.67x	-4.12x	-3.61x	-2.43x	-6.35x	-6.34x	-8.60x	-6.20x
FCF Conversion	-0.13x	2.25x	0.80x	0.95x	0.75x	-0.07x	0.66x	0.77x	0.79x	0.67x
Revenue Growth	-38.95%	271.3%	-87.44%	135.64%	-14.71%	107.79%	26.15%	34.3%	-92.04%	145.34%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
Collaboration Revenues	-	-	-	-	-	-	3.47M
Collaboration Revenues Growth	-	-	-	-	-	-	-
Research And Development	-	-	-	10.57M	6.59M	4.03M	-
Research And Development Growth	-	-	-	-	-37.68%	-38.83%	-
Milestone	-	-	-	-	1M	3.5M	-
Milestone Growth	-	-	-	-	-	250.00%	-
License	5.13M	-	-	-	-	-	-
License Growth	-	-	-	-	-	-	-
Research And Development Milestone Grant And Other Revenues Net	-	13.8M	10M	7.4M	-	-	-
Research And Development Milestone Grant And Other Revenues Net Growth	-	-	-27.54%	-26.00%	-	-	-
Reimbursements	22.25M	13.11M	6.55M	-	-	-	-
Reimbursements Growth	-	-41.10%	-49.98%	-	-	-	-
Milestone Fees	2M	-	-	-	-	-	-
Milestone Fees Growth	-	-	-	-	-	-	-
Co Invest Option Payments	-	-	-	-	-	-	-
Co Invest Option Payments Growth	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Cytokinetics, Incorporated (CYTK) reported $87.2M in revenue for fiscal year 2024. This represents a 2080% increase from $4.0M in 2011.

Cytokinetics, Incorporated (CYTK) grew revenue by 145.3% over the past year. This is strong growth.

Cytokinetics, Incorporated (CYTK) reported a net loss of $751.9M for fiscal year 2024.

Dividend & Returns

Cytokinetics, Incorporated (CYTK) had negative free cash flow of $453.4M in fiscal year 2024, likely due to heavy capital investments.